Through numerous clinical studies, Dr. Ricardo Rosales and his colleagues have demonstrated the therapeutic potential of this vaccine technology in the treatment of cancer and pre-cancerous lesions. For example, the recombinant MVA E2-based vaccine was effective in eradicating lesions in patients with recurrent respiratory papillomatosis – a disease caused by HPV 6 and 11. Patients who received the vaccine generated an immune response that targeted and eliminated HPV-infected cells, providing long-term protection against lesion recurrence.

Another phase 3 clinical trial involved over a thousand patients with HPV-induced lesions that can lead to cervical and anal cancer. The lesions were completely eliminated in 9 out of 10 of patients, with no recurrences after 10 years of follow up.

While the cancer applications of the team’s vaccines are the main focus, their origins in smallpox vaccine research are significant. Dr. Ricardo Rosales’ work has also led to the development of a preventive vaccine for monkeypox and smallpox using GAB-1. A single dose of the GAB-1 vaccine provides protection for decades, with no adverse side effects, highlighting its potential in public health preparedness.

The pioneering efforts of Dr. Ricardo Rosales and his team demonstrate how a virus once used to combat a historic disease can be repurposed to tackle modern health crises, from emerging infectious diseases to cancer.